Use of drotrecogin alfa (activated) in two patients with severe sepsis

Medical Science Monitor

Volumn 9, Issue 8, 2003, Pages

  Mikaszewska Sokolewicz, Małgorzata ^a   Nierebińska, Małgorzata ^a   Mayzner Zawadzka, Ewa ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Crush syndrome; Drotrecogin alfa (activated); Recombinant human activated protein C; Septic shock; Severe sepsis

Indexed keywords

DOBUTAMINE; DROTRECOGIN;

ABSCESS DRAINAGE; ADULT; ARTICLE; CASE REPORT; CRUSH TRAUMA; DISEASE SEVERITY; HUMAN; INTENSIVE CARE UNIT; KIDNEY FAILURE; LIVER ABSCESS; MALE; MULTIPLE ORGAN FAILURE; SEPSIS; SEPTIC SHOCK; TREATMENT OUTCOME;

ADULT; ANTI-INFECTIVE AGENTS; HUMANS; MALE; MIDDLE AGED; MULTIPLE ORGAN FAILURE; PROTEIN C; RADIOGRAPHY, THORACIC; RECOMBINANT PROTEINS; SEPSIS;

EID: 0141595218     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bone RC et al: Definition of Sepsis and Organ Failure Guidelines for Use of Innovative Therapies in Sepsis. Chest, 1992; 101: 1644-1655
2. Levy MM et al: 2001 SCCM/ESICM/ACCP/ATS/SIS International Sespis Definitions Conference. Intensive Care Med, 2003; 29: 530-538
3. Angus DC et al: Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated cost of care. Crit Care Med, 2001; 29(7); 1303-1310
4. Davis A et al: Severe sepsis: A European estimate of the burden of disease in ICU. Intens. Care Med, 2001; 27: abstr # 581
5. Jacobi J: Sepsis: A frequent, life-threatening syndrome. Pharmacotherapy, 2002; 22(12): 169-181
6. Vincent JL: Microvascular endothelial dysfunction: a renewed appreciation of sepsis pathophysiology. Critical Care, 2001; 5: 1-5
7. Esmon CT: The normal role of Activated Protein C in maintaining homeostasis and its relevance to critical illness. Critical Care, 2001; 5: 7-12
8. Bernard GR et al: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med, 2001; 344: 699-709
9. Vincent JP et al: The sepsis text. Kluwer Academic Publishers, 2002; ISBN 0-7923-7620-X: 11-29
10. Eli Lilly - data on file
11. Rudis MI et al: Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). Pharmacotherapy, 2002; 22: 182-195
12. McCoy C et al: Drotrecogin alfa (Recombinant Human Activated Protein C) for the treatment of severe sepsis. Clinical Therapeutics, 2003; 25: 396-421
13. Bernard GR: Drotercogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Crit Care Med. 2003; 31: 85-93
14. Healy DP: New and emerging therapies for sepsis. The Annals of Pharmacotherapy, 2002; 36: 648-654
15. Ely WE et al: Drotercogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med, 2003; 31: 12-18
16. Sprung LC et al: Summary of recommendation. Intensive Care Med, 2001; 27: 128-134
17. Sesler CN et al: New concepts in sepsis. Current Op Crit Care, 2002; 8: 465-472
18. Hotchkiss RS et al: The pathophysiology and treatment of sepsis. N Engl J Med, 2003; 348: 138-150
19. Laterre PF et al: Management of patients with severe sepsis, treated by drotrecogin alfa (activated). Am J Surg, 2002; 184: 30-46